)

Neumora Therapeutics (NMRA) investor relations material
Neumora Therapeutics H.C. Wainwright 27th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Obesity and NLRP3 Inhibitor Program
NLRP3 inhibitor targets CNS-mediated pathways to suppress appetite, offering a novel mechanism distinct from incretins and amylins.
Oral, once-daily small molecule formulation aims for high brain penetration, improved tolerability, and affordability compared to injectables.
Upcoming DIO mouse model data expected later this year will inform clinical development, with monotherapy, combination, and maintenance paradigms under evaluation.
Plans to enter clinical trials in 2026, starting with monotherapy and expanding to combination and maintenance studies if preclinical data supports.
Potential benefits include lean muscle mass sparing, reduced GI side effects, and broader metabolic and cardiovascular utility.
M4 PAM Franchise and Clinical Strategy
Two M4 positive allosteric modulators (PAMs) are advancing, with one in phase 1 and another entering the clinic by year-end, both optimized for brain penetration and safety.
The franchise approach allows for targeting multiple neuropsychiatric and neurodegenerative indications, including schizophrenia and dementia-related psychosis.
Phase 1 studies include stable schizophrenia patients to assess dose tolerance, PK, and side effect profiles, with prioritization of the lead asset for proof-of-concept studies.
Early data will guide whether both assets pursue schizophrenia or diverge into other indications.
Updates on Coastal and 511 Programs
Coastal studies were paused and refined to improve patient selection and site quality, with new screening processes to ensure higher data integrity.
Enrollment guidance for COSTAL 2 and 3 remains for 2026, with operational changes expected to address prior placebo response issues.
The 511 program targets Alzheimer's agitation, with phase 1b data expected by year-end; aims for better tolerability than current therapies and focuses on outpatient populations.
Next Neumora Therapeutics earnings date

Next Neumora Therapeutics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage